Cargando…
Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil
INTRODUCTION: Advances in comprehensive genomic profiling (CGP) of lung adenocarcinomas (LUADs) led to personalized treatment for patients. This study evaluated medical oncologists’ attitudes toward CGP in a scenario where sponsored funding for CGP was available. METHODS: We designed an online surve...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526154/ https://www.ncbi.nlm.nih.gov/pubmed/36193188 http://dx.doi.org/10.1016/j.jtocrr.2022.100402 |
_version_ | 1784800815838396416 |
---|---|
author | Fares, Aline F. Martinez, Pedro H. Farina, Pedro H. Bicalho de Souza, Isaac Araújo, Daniel V. Paiva, Narayana S. Orlando, Ligia F. Colombo, Tatiana Elias Mascarenhas, Eldsamira Gelatti, Ana Caroline Z. Baldotto, Clarissa Zukin, Mauro Araujo, Luiz Henrique Mathias, Clarissa Werutsky, Gustavo de Castro, Gilberto Cordeiro de Lima, Vladmir C. |
author_facet | Fares, Aline F. Martinez, Pedro H. Farina, Pedro H. Bicalho de Souza, Isaac Araújo, Daniel V. Paiva, Narayana S. Orlando, Ligia F. Colombo, Tatiana Elias Mascarenhas, Eldsamira Gelatti, Ana Caroline Z. Baldotto, Clarissa Zukin, Mauro Araujo, Luiz Henrique Mathias, Clarissa Werutsky, Gustavo de Castro, Gilberto Cordeiro de Lima, Vladmir C. |
author_sort | Fares, Aline F. |
collection | PubMed |
description | INTRODUCTION: Advances in comprehensive genomic profiling (CGP) of lung adenocarcinomas (LUADs) led to personalized treatment for patients. This study evaluated medical oncologists’ attitudes toward CGP in a scenario where sponsored funding for CGP was available. METHODS: We designed an online survey assessing CGP use and treating physicians’ confidence, composed of three self-confidence domains, which are as follows: confidence in interpreting CGP results, confidence in treating oncogenic-driven LUAD, and confidence in managing tyrosine kinase inhibitor adverse events. The survey was distributed to medical oncologists who treat lung cancer in Brazil. Comparisons between groups were performed using the chi-square or Fisher’s exact test. Univariable and multivariable (adjusted OR) analyses were performed. RESULTS: Among 104 respondents who treat patients with lung cancer, 55% were from the Southeast region, 28% had high lung cancer clinical load, and 33% had in-house molecular testing. More than half (51%) of the participants request CGP systematically to stage IV LUAD. As for provider confidence, 67% stated being confident in all three domains: 76% confident in interpreting CGP, 84% confident in treating oncogenic-driven LUAD, and 81% in managing tyrosine kinase inhibitor adverse events. Providers’ confidence was associated with systematically requesting CGP to stage IV LUAD (p = 0.013). After controlling for the variables of interest, systematic requesting CGP for stage IV LUAD revealed a significant association with the provider’s confidence (adjusted OR = 0.35, p = 0.028, 95% CI: 0.14–0.84). The major challenge for properly requesting CGP was the long turnaround time and the fear of treatment delays. CONCLUSIONS: Even though CGP for stage IV LUAD in Brazil is fully sponsored, only half of the oncologists in our survey systematically request it.. Requesting CGP was associated with providers’ confidence. Improving access and promoting providers’ awareness of CGP utility is necessary to increase CGP use and better inform treatment decisions. |
format | Online Article Text |
id | pubmed-9526154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95261542022-10-02 Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil Fares, Aline F. Martinez, Pedro H. Farina, Pedro H. Bicalho de Souza, Isaac Araújo, Daniel V. Paiva, Narayana S. Orlando, Ligia F. Colombo, Tatiana Elias Mascarenhas, Eldsamira Gelatti, Ana Caroline Z. Baldotto, Clarissa Zukin, Mauro Araujo, Luiz Henrique Mathias, Clarissa Werutsky, Gustavo de Castro, Gilberto Cordeiro de Lima, Vladmir C. JTO Clin Res Rep Original Article INTRODUCTION: Advances in comprehensive genomic profiling (CGP) of lung adenocarcinomas (LUADs) led to personalized treatment for patients. This study evaluated medical oncologists’ attitudes toward CGP in a scenario where sponsored funding for CGP was available. METHODS: We designed an online survey assessing CGP use and treating physicians’ confidence, composed of three self-confidence domains, which are as follows: confidence in interpreting CGP results, confidence in treating oncogenic-driven LUAD, and confidence in managing tyrosine kinase inhibitor adverse events. The survey was distributed to medical oncologists who treat lung cancer in Brazil. Comparisons between groups were performed using the chi-square or Fisher’s exact test. Univariable and multivariable (adjusted OR) analyses were performed. RESULTS: Among 104 respondents who treat patients with lung cancer, 55% were from the Southeast region, 28% had high lung cancer clinical load, and 33% had in-house molecular testing. More than half (51%) of the participants request CGP systematically to stage IV LUAD. As for provider confidence, 67% stated being confident in all three domains: 76% confident in interpreting CGP, 84% confident in treating oncogenic-driven LUAD, and 81% in managing tyrosine kinase inhibitor adverse events. Providers’ confidence was associated with systematically requesting CGP to stage IV LUAD (p = 0.013). After controlling for the variables of interest, systematic requesting CGP for stage IV LUAD revealed a significant association with the provider’s confidence (adjusted OR = 0.35, p = 0.028, 95% CI: 0.14–0.84). The major challenge for properly requesting CGP was the long turnaround time and the fear of treatment delays. CONCLUSIONS: Even though CGP for stage IV LUAD in Brazil is fully sponsored, only half of the oncologists in our survey systematically request it.. Requesting CGP was associated with providers’ confidence. Improving access and promoting providers’ awareness of CGP utility is necessary to increase CGP use and better inform treatment decisions. Elsevier 2022-08-30 /pmc/articles/PMC9526154/ /pubmed/36193188 http://dx.doi.org/10.1016/j.jtocrr.2022.100402 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Fares, Aline F. Martinez, Pedro H. Farina, Pedro H. Bicalho de Souza, Isaac Araújo, Daniel V. Paiva, Narayana S. Orlando, Ligia F. Colombo, Tatiana Elias Mascarenhas, Eldsamira Gelatti, Ana Caroline Z. Baldotto, Clarissa Zukin, Mauro Araujo, Luiz Henrique Mathias, Clarissa Werutsky, Gustavo de Castro, Gilberto Cordeiro de Lima, Vladmir C. Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil |
title | Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil |
title_full | Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil |
title_fullStr | Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil |
title_full_unstemmed | Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil |
title_short | Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil |
title_sort | assessing oncologists’ attitudes concerning comprehensive genomic profiling in stage iv lung adenocarcinoma in brazil |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526154/ https://www.ncbi.nlm.nih.gov/pubmed/36193188 http://dx.doi.org/10.1016/j.jtocrr.2022.100402 |
work_keys_str_mv | AT faresalinef assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT martinezpedroh assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT farinapedroh assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT bicalhodesouzaisaac assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT araujodanielv assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT paivanarayanas assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT orlandoligiaf assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT colombotatianaelias assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT mascarenhaseldsamira assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT gelattianacarolinez assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT baldottoclarissa assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT zukinmauro assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT araujoluizhenrique assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT mathiasclarissa assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT werutskygustavo assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT decastrogilberto assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil AT cordeirodelimavladmirc assessingoncologistsattitudesconcerningcomprehensivegenomicprofilinginstageivlungadenocarcinomainbrazil |